The short answer
Bonaca and colleagues published STRIDE in the Lancet in May 2025: a phase 3b, double-blind randomised trial of semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes.
Key facts
- Trial
- STRIDE
- Published
- Lancet, 3 May 2025 (PMID 40169145)
- Design
- Phase 3b, double-blind, randomised
- Population
- Symptomatic PAD and type 2 diabetes
- Endpoint
- Walking capacity
- Subgroup analysis
- Rasouli 2025 (PMID 40543068)
The qualifier in the title
The trial enrolled people with symptomatic peripheral artery disease AND type 2 diabetes. That second criterion appears in the published title and is routinely dropped when the result is summarised as semaglutide improving walking in peripheral artery disease. It defines who the finding applies to, and dropping it widens the claim beyond what was studied.
Why walking capacity is the right endpoint
The defining symptom of peripheral artery disease is claudication, pain on walking that limits how far a person can go. Measuring walking distance tests the thing the condition actually does to people, rather than a surrogate such as an imaging measure or an ankle pressure index. It is a functional endpoint, which is generally harder to move and more meaningful when it does move.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Why a functional endpoint is unusual in this literature
Most incretin trials report weight, glycaemic measures or event counts. A trial whose primary question is how far someone can walk is asking about capability rather than biology, and that connects to the body composition discussion elsewhere on this site: functional measures test whether a change in composition or physiology matters to what a person can do.
What the subgroup analysis examined
Rasouli and colleagues published on benefit by baseline type 2 diabetes characteristics in Diabetes Care in September 2025. Subgroup analyses within a randomised trial examine whether an effect is consistent across the enrolled population, and they are hypothesis-generating rather than definitive because the trial was not randomised within subgroups.
What this adds to the indication picture
Cardiovascular events in SELECT, kidney events in FLOW, liver histology in ESSENCE, heart failure in STEP-HFpEF and now walking capacity in peripheral artery disease. The pattern across these is a metabolic agent being assessed organ system by organ system, and reported as under regulatory review for indications beyond weight.
The boundary
Semaglutide is a licensed medicine and STRIDE was a registered randomised trial conducted under clinical supervision. Nothing supplied on this site is semaglutide or is an alternative to any treatment for peripheral artery disease.
Frequently asked questions
Who was enrolled in STRIDE?
People with symptomatic peripheral artery disease and type 2 diabetes. The diabetes criterion is in the published title and is often dropped in summaries.
Why measure walking capacity?
Claudication (pain limiting walking distance) is the defining symptom, so it tests what the condition actually does rather than a surrogate.
What did the subgroup analysis show?
Rasouli 2025 examined benefit by baseline diabetes characteristics. Subgroup analyses within a trial are hypothesis-generating rather than definitive.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedBonaca MP et al., Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised trial. Lancet 2025 (PMID 40169145)pubmed.ncbi.nlm.nih.gov
- PubMedRasouli N et al., Benefit of Semaglutide in Symptomatic Peripheral Artery Disease by Baseline Type 2 Diabetes Characteristics: Insights From STRIDE. Diabetes Care 2025 (PMID 40543068)pubmed.ncbi.nlm.nih.gov
- PubMedKosiborod MN et al. NEJM 2023 (PMID 37622681)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Research & Regulatory News articles
- A Trial That Had to Move Two Things at Once407 participants, Phase 3, with co-primary endpoints of body weight and WOMAC pain score. Published in NEJM in October 2024.
- A Nationwide Cohort, and a Result That Points Away From the DrugDanish registries, 2009 to 2023. Preterm birth risk was raised in the diabetes indication but not in weight management - which is the finding.
- Canada in January, India in MarchCanada became the first G7 nation where semaglutide patents expired, on 4 January 2026. India followed in March, with generics reported at 70-90% discounts.
- Two Pathways, Two TimescalesA generic drug shows bioequivalence. A biosimilar shows no clinically meaningful difference. The 40-residue line decides which applies.
- Comparing an Operation With an InjectionA 2026 network meta-analysis compared metabolic and bariatric surgery against GLP-1 receptor agonists. Why the comparison is harder than it looks.